



Biotech Daily

Tuesday July 27, 2021

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: STARPHARMA UP 8%; PRESCIENT DOWN 16%**
- * **PRESCIENT: SAFETY TAKES PTX-100 TO CANCER EXPANSION STUDY**
- * **SOMNOMED RECEIPTS DOWN 3% TO \$60m**
- * **ALCIDION RECEIPTS UP 54% TO \$32m**
- * **ALTHEA RECEIPTS UP 126% TO \$10.3m**
- * **IMPEDIMED RECEIPTS UP 44% TO \$8m**
- * **CONTROL BIONICS POSTS \$3.3m**
- * **MGC RECEIPTS UP 26.5% TO \$2.7m**
- * **AUDEARA POSTS \$1.2m RECEIPTS**
- * **CONTROL BIONICS APPOINTS DNR WHEELS SINGAPORE RESELLER**
- * **US ALLOWS MEDLAB NRGBIOTIC FOR DEPRESSION PATENT**
- * **INCANNEX STARTS PHASE I IHL-675A SAFETY TRIAL; PATENT**
- * **STARPHARMA: 'SPL7013 KILLS 99.9% OF DELTA, KAPPA SARS-COV-2'**
- * **AROA REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **IMUGENE REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **CTXONE RENAMES ITSELF ONCOLOGY ONE**
- * **FACTOR TO BUY POWERLIME, BECOME DOMINION MINERALS**
- * **DR ALAN FINKEL, NEBULA, HOWITT BELOW 5% OF COGSTATE**
- * **SEAN WILLIAMS REPLACES LIFESPOT CHAIR RODNEY HANNINGTON**

MARKET REPORT

The Australian stock market was up 0.5 percent on Tuesday July 27, 2021, with the ASX200 up 37.1 points to 7,431.4 points.

Ten of the Biotech Daily Top 40 stocks were up, 21 fell, eight traded unchanged and one was untraded.

Starpharma was the best, up 10 cents or 7.9 percent to \$1.36, with 1.6 million shares traded. LBT improved 4.55 percent; Cynata was up three percent; Amplia and Proteomics rose more than two percent; with Cyclopharm, Genetic Signatures, Nova Eye, Pharmaxis and Polynovo up by less than one percent.

Prescient led the falls, down 3.5 cents or 16.3 percent to 18 cents, with 23.8 million shares traded.

Impedimed lost 8.6 percent; Resonance retreated 6.25 percent; Osprey was down 5.9 percent; Actinogen fell 4.35 percent; Medical Developments, Next Science and Universal Biosensors were down three percent or more; Clinuvel, Dimerix, Immutep, Mesoblast, Nanosonics and Patrys shed more than two percent; Cochlear, Compumedics, Kazia, Opthea, Pro Medicus, Resmed and Volpara lost more than one percent; with Avita, CSL and Neuren down by less than one percent.

PRESCIENT THERAPEUTICS

Prescient says it will develop PTX-100 as a monotherapy for T-cell lymphoma, and expand its phase Ib cancer study for cancer which showed an “excellent” safety profile. In 2019, Prescient dosed the first of up-to 24 patients in the trial of PTX-100 for solid and blood cancers (BD: Nov 14, 2019).

Today, the company said that 10 patients had been enrolled in the “basket” trial and five patients with solid tumors and five with haematological, or blood, malignancies dosed with PTX-100 ranging from 500mg/m² to 2,000mg/m², with PTX-100 well tolerated to the highest dose of 2,000 /m².

Prescient said several adverse events were observed but did not determine them to be related to the drug.

The company said it observed clinical benefit in two patients with T-cell lymphoma with aggressive disease that had previously failed three to five therapies.

Prescient said that two patients remained on the treatment for 12 to 17 months, with current average life expectancy for patients four months with standard care.

The company said the expansion study would be led by Melbourne-based Epworth Hospital’s Prof Miles Prince and was expected to enrol up to 12 patients and focus on relapsed, refractory, and peripheral T-cell lymphoma.

Prof Prince said the safety profile of PTX-100 was “impressive, with the drug very well tolerated at all dose levels”.

“It was also very encouraging to see early clinical activity, Prof Prince said.

“The two patients that responded had aggressive disease and had quickly progressed on previous therapies,” Prof Prince said.

“It was surprising to not only see clinical responses in these patients, but for these benefits to endure for a year or longer, together with symptomatic relief,” Prof Prince said.

Prescient fell 3.5 cents or 16.3 percent to 18 cents with 23.8 million shares traded.

SOMNOMED

Somnomed says receipts from customers for the year to June 30, 2021 was down 3.0 percent to \$59,703,000 compared to the previous corresponding period.

Somnomed said that receipts from customers for its treatments for sleep-related breathing disorders and obstructive sleep apnoea for the three months to June 30, 2021 was up 28.4 percent to \$15,519,000.

The company said it had net cash for the three months of \$747,000 with cash and cash equivalents of \$21,381,000 at June 30, 2021 compared to the \$30,174,000 at June 30, 2020.

Somnomed was up 15 cents or 6.7 percent to \$2.39.

ALCIDION

Alcidion says that receipts from customers for the year to June 30, 2021 was up 54.0 percent to \$32,046,000 compared to previous corresponding period.

Alcidion said that receipts for the three months to June 30, 2021 improved 27.1 percent to \$9,703,000, primarily from sales and use of its hospital management systems.

The company said it had record unaudited annual revenue up 38 percent to 39 percent to about \$25.6 million to \$25.9 million with a full year positive cashflow of \$1.1 million.

Alcidion was up five cents or 14.1 percent to 40.5 cents with 6.9 million shares traded.

ALTHEA GROUP HOLDINGS

Althea says receipts from customers for the year to June 30, 2021 was up 125.7 percent to \$10,298,000 compared to the previous corresponding period.

Althea said that receipts from customers for its marijuana products for the three months to June 30, 2021 was up 86.1 percent to \$2,848,000.

The company said it had estimated 2.59 quarters of funding available compared to the 6.18 quarters of funding available in the previous corresponding period

Althea was up half a cent or 1.6 percent to 32.5 cents.

IMPEDIMED

Impedimed says that receipts from customers for the year to June 30, 2021, was up 43.6 percent to \$7,732,000 compared to the previous corresponding period.

Impedimed said that receipts for the three months to June 30, 2021, improved 65.2 percent to \$2,276,000 primarily from sales and software as a service revenue from its Sozo and bio-impedance spectroscopy.

The company it had record revenue of \$2.6 million for the three months to June 30, 2021.

Impedimed said it had a cash burn for the three months to June 30, 2021 of \$835,000, with cash and cash equivalents of \$19,861,000.

Impedimed fell 0.9 cents or 8.6 percent to 9.6 cents with 9.1 million shares traded.

CONTROL BIONICS

Control Bionics says receipts from customers for the year to June 30, 2021 was \$3,333,000 and for the three months to June 30, 2021 was \$1,052,000.

Last year, Control Bionics raised \$15 million to list on the ASX to commercialize its disability-aiding communication devices (BD: Nov 27, 2020).

Control Bionics was up half a cent or 0.8 percent to 62.5 cents.

MGC PHARMACEUTICALS

MGC says receipts from customers for the year to June 30, 2021 was up 26.5 percent to \$2,672,000 compared to the previous corresponding period.

MGC said that receipts from customers for its marijuana-derived products for the three months to June 30, 2021 was up 232.4 percent to \$1,303,000.

The company said it had 4.43 quarters of funding available compared to the one quarter of funding available in the previous corresponding period.

MGC fell 0.1 cents or 2.5 percent to 3.9 cents with 9.1 million shares traded.

AUDEARA

Audera says receipts from customers for its hearing products for the year to June 30, 2021 was \$1,184,000 and for the three months to June 30, 2021 was \$349,000.

In May, Brisbane's Audera raised \$7 million to list on the ASX (BD: May 10, 2021).

Audera was up half a cent or 4.8 percent to 11 cents.

CONTROL BIONICS

Control Bionics says it has appointed DNR Wheels as its exclusive reseller of its assistive communication products for people with disabilities in Singapore.

Control Bionics said there was no minimum purchase requirements, with prices set in the reseller agreement.

The company said the agreement with the Singapore-based DNR Pte Ltd was part of its "strategy to access the international rehabilitation market".

MEDLAB CLINICAL

Medlab says the US Patent and Trademark Office has allowed a patent covering its NRGBiotic for depression.

Medlab said when granted, the patent, titled 'Composition for treating, preventing, or Ameliorating depression or a Depressive disorder', would protect its intellectual property until 2035, covering the formulation of NRGBiotic and a method for treating, preventing, or ameliorating at least one symptom of depression or a depressive disorder.

Medlab was up half a cent or 2.8 percent to 18.5 cents.

INCANNEX HEALTHCARE

Incannex says it has begun a 36-participant, phase I safety trial of its cannabidiol and hydroxychloroquine IHL-675A soft gel capsules and has filed a patent application.

Incannex said the trial would have three arms comparing the combination IHL-675A with cannabidiol alone and hydroxychloroquine alone and would include safety and pharmacokinetic assessments.

The company said it expected recruitment to begin by the end of this year.

Incannex said it had filed a patent application under the Patent Cooperation Treaty titled, 'Methods and compositions for treating or preventing an inflammatory condition', relating to IHL-675A, but failed to specify where the patent was filed, or its duration.

The company said that, if successful, results from the trial would form three US Food and Drug Administration investigational new drug applications for the prevention and treatment of inflammatory lung conditions, rheumatoid arthritis, and inflammatory bowel disease.

Incannex was unchanged at 25.5 cents with 1.9 million shares traded.

STARPHARMA

Starpharma says SPL7013 reduces the Delta and Kappa variants of severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) by “more than 99.9 percent”, in-vitro. Starpharma said the Federal Government’s Medical Research Future Fund awarded it \$1 million for its Viraleze nasal delivery system for the anti-microbial SPL7013, the active ingredient in its Vivagel BV for bacterial vaginosis and condom coatings.

Today, the company said that the testing of SPL7013 against the delta strain was conducted at the San Diego, California-based Scripps Research Institute.

Starpharma said that SPL7013 showed “potent virucidal activity” reducing the Delta variant by more than 99.99 percent and the Kappa strain by more than 99.9 percent within 30 seconds of exposure.

Scripps virologist Prof Philippe Gallay said it was “remarkable that SPL7013 has demonstrated potent anti-Sars-Cov-2 activity against the broad-spectrum of variants of concern, Alpha, Beta, Gamma, and now importantly Delta, and ... Kappa, in vitro”.

Starpharma chief executive officer Dr Jackie Fairley said that SPL7013 had “a deep pedigree as an anti-viral compound, with consistent and compelling broad-spectrum activity against multiple respiratory viruses and now multiple variants of Sars-Cov-2”. Starpharma was up 10 cents or 7.9 percent to \$1.36 with 1.6 million shares traded.

AROA BIOSURGERY

Aroa has requested a trading halt “pending an announcement by the company to the market regarding a capital raising”.

Trading will resume on July 29, 2021 or on an earlier announcement.

Aroa last traded at \$1.185.

IMUGENE

Imugene has requested a trading halt “pending an announcement in relation to a capital raising”.

Trading will resume on July 29, 2021 or on an earlier announcement.

Imugene last traded at 33 cents.

CTXONE, ONCOLOGY ONE PTY LTD

Melbourne’s CTx One Pty Ltd says it has re-named itself Oncology One Pty Ltd to raise capital for its small molecule cancer drug discovery projects.

Oncology One said it was “the original management company and then a commercialization partner of the Cooperative Research Centre [CRC] for Cancer Therapeutics, a 2007 collaboration of research institutes, universities and companies.

The company said it had licenced technology “related to a class of cancer drugs” to Pfizer in 2018, in a deal worth up to \$US475 million in development milestones, with additional royalties on sales if the technology was successful.

Oncology One said that PF-07248144 began phase I clinical trials last year for the potential treatment of patients with advanced or metastatic breast, prostate or lung cancer.

Oncology One chief executive officer Dr Joanne Boag said the company had “a number of projects in partnership with research institutions coming online over the next month”.

Dr Boag said the company’s goal was “to progress small molecule oncology drug development programs towards the clinic”.

Oncology One is a private company.

[FACTOR THERAPEUTICS \(FORMERLY TISSUE THERAPIES\)](#)

Factor says it will acquire all issued Powerlime shares, move to the resources sector and rename itself Dominion Minerals.

In April, Factor said that, pending due diligence and approvals the Early County, South Georgia-based Power Lime would be acquired and become a wholly owned subsidiary of Factor, which would become a resources company (BD: Apr 21, 2021).

In 2008, the then Tissue Therapies was developing Vitrogro as a wound treatment for venous ulcers, claiming “excellent results” ($p < 0.0001$) from a 30-patient study, but was unable to obtain Conformité Européenne (CE) mark approval, expected since 2012, but with repeated delays the company lost the services of chief executive officer Dr Steven Mercer (BD: Jul 9, 2008; Sep 30, 2010; Sep 30, 2011; Apr 7, 2015).

In 2018, Factor fell from 7.3 cents to 0.2 cents on news that its 157-patient, phase II trial of VF001 for venous leg ulcers “failed to meet all endpoints” (BD: Nov 14, 2018).

Effectively, the company has been a shell looking for an acquisition since the trial.

Today, Factor said that following the close of the transaction it would seek to be reinstated on the ASX and it had commitments to raise \$4 million in a capital raising at 0.4 cents a share.

The company said that following the transaction, it proposed to change its name to Dominion Minerals with the ASX ticker code ‘DML’.

Factor was in a suspension and last traded at 0.5 cents.

[COGSTATE](#)

Former chief scientist Dr Alan Finkel and associates have ceased to be substantial shareholders in Cogstate.

The former Cogstate director, Dr Finkel said that through Nebula Neuro and Howitt Nominees he sold 1,175,634 shares for \$1,767,106 or \$1.503 a share.

Cogstate was up five cents or 2.9 percent to \$1.80.

[LIFESPOT HEALTH](#)

Lifespot says it has appointed Sean Williams as a non-executive director and chair replacing Rodney Hannington, effective immediately.

Lifespot said Mr Hannington was the chair of the company since April 2008 and thanked him for his “dedicated service”.

The company said Mr Williams was an executive and mostly recently the chief executive officer of an undisclosed agricultural investment company.

Lifespot said Mr Williams began his career at KPMG, and was previously Symbion Pharmacy Services’ finance general-manager and Silk Logistics chief financial officer.

Lifespot was untraded at 10 cents.